A Phase 1, Open-Label, Single-Dose, Parallel Group, 2-Part Study to Evaluate the Pharmacokinetics of Bepirovirsen in Adult Participants With Severe or Moderate Renal Impairment Compared to Matched Healthy Control Participants
Latest Information Update: 21 Oct 2025
At a glance
- Drugs Bepirovirsen (Primary)
- Indications Renal impairment
- Focus Pharmacokinetics
- Acronyms B-Kind
- Sponsors GSK
Most Recent Events
- 15 Oct 2025 Status changed from not yet recruiting to recruiting.
- 18 Sep 2025 New trial record